Bausch + Lomb Corporation (BLCO)

From the record

Bausch + Lomb Corporation's filings since 2021 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Bausch + Lomb Corporation's 6 filed years say what it did: revenue went from $3.4 billion in fiscal 2020 to $5.1 billion in fiscal 2025, up 8.4% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 2 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Bausch + Lomb Corporation's diluted share count grew about 0.3% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 4 sales and 9 purchases of their own stock on the open market in the year to 2026-11-02, buying about $1 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bausch + Lomb Corporation lost about 6 cents for every dollar of shareholders' money. Leverage: it owed about 54 cents per dollar of assets, and net share issuance: its share count grew 0.6% over the year (the filed statements).

From the record

Bausch + Lomb Corporation's standing among 8 graded names in its industry family: revenue of $5.1 billion in fiscal 2025 ranks in the top 19% by size; a net margin of -7.1% ranks in the bottom 44%; revenue growth of 10.6% a year over the last 3 filed years ranks in the top 44% (its annual reports).

From the record

Bausch + Lomb Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Saunders, Brent L (Chairman of the Board and CEO, as filed), filing under that title since 2023-03-06, 3.7 years (top 42% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 3.6 years (bottom 42%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (top 36%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Bausch + Lomb Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $397 million against debt of $5.0 billion leaves -33% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is -1.3% of revenue (bottom 44%); research spending of 7.3% of revenue (bottom 25%) (its annual report).

From the record

Bausch + Lomb Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 10.6% a year over the last three filed years against 8.4% over all 6, speeding up (top 19% of its family); the newest year grew 6.5% (top 44%); research spending grew 6.5% a year (bottom 25%); capital spending grew 25.9% a year (top 6%) (its annual reports). Bausch + Lomb Corporation reported 3 lines of business in fiscal 2025: Vision Care at $2.9 billion (57%), Pharmaceuticals at $1.3 billion (25%), Surgical at $894 million (18%); 3 of 3 grew against the year before (its annual report).

From the record

Bausch + Lomb Corporation's newest year against its own record: revenue of $5.1 billion in fiscal 2025 came in 5.6% below the $5.4 billion its prior three years' pace pointed to (bottom 31% of its family); net income of $360 million against a prior three-year average of $190 million (bottom 19%); a net margin of -7.1% against -4.2% before (bottom 19%) (its annual reports).